Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues.
The number of allogeneic hematopoietic stem cell (HSC) transplants performed globally each year continues to increase. Advances in HLA typing, better supportive care, and administration of reduced-intensity conditioning regimens allow treatment of older patients with older sibling donors. Pretransplant donor assessment and testing are very important processes affecting the quality and safety of donation. For unrelated HSC donors detailed recommendations for health assessment have been published, allowing donation only if they are unrestrictedly healthy. Eligibility criteria for related donors are less strict and vary significantly between centers. In situations where a family donor does not meet the suitability criteria for unrelated donors, involved physicians often struggle with the decision whether the matched relative is suitable for donation or not. On behalf of the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues, we intended to develop a consensus document with recommendations for donor workup and final clearance of family donors who would not be able to serve as unrelated donors because of their age or pre-existing diseases. This article covers different topics intending to support decision-making, with the goal of minimizing medical risk to the donor and protection of the recipient from transmissible diseases.
Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria. Electronic address: nina.worel@meduniwien.ac.at.
Nina
N
Worel
Blood Transfusion Centre, Swiss Red Cross, Basel, Switzerland; Department of Hematology, University Hospital Basel, Basel, Switzerland.
Andreas
A
Buser
Division of Hematology, Medical University of Graz, Graz, Austria.
Hildegard T
HT
Greinix
Division of Hematology, Department of Medical Sciences Uppsala University, Uppsala, Sweden.
Hans
H
Hägglund
National Marrow Donor Program, Minneapolis, Minnesota.
Willis
W
Navarro
Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute/University of Utah, Primary Children's Hospital, Salt Lake City, Utah.
Michael A
MA
Pulsipher
Swiss Blood Stem Cell, Bern, Switzerland.
Grazia
G
Nicoloso de Faveri
Tobias Registry of Swedish Bone Marrow Donors and Uppsala University, Department of Immunology, Genetics and Pathology, Uppsala, Sweden.
Mats
M
Bengtsson
Anthony Nolan, UCL Cancer Institute, London, United Kingdom.
Annelies
A
Billen
Department of Internal Medicine, Hematology and Bone Marrow Transplantation Section, University Hospital Caja del Seguro Social, Panama City, Panama.
German
G
Espino
Europdonor Foundation Leiden, Leiden University Medical Centre, Leiden, The Netherlands.
Mirjam
M
Fechter
Department of Immunohematology and Transfusion Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.
Valeria
V
Giudice
Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Kristina
K
Hölig
Department of Hematology, Kanagawa Cancer Center, Kanagawa, Japan.
Heiwa
H
Kanamori
Asia-Pacific Blood and Marrow Transplantation Group and Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan.
Yoshihisa
Y
Kodera
Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.
Gerda
G
Leitner
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Tanja
T
Netelenbos
Department of Hematology, University Hospital Leipzig, Leipzig, Germany.
Dietger
D
Niederwieser
Europdonor Foundation Leiden, Leiden University Medical Centre, Leiden, The Netherlands; Ethics Working Group of the World Marrow Donor Association, Leiden, The Netherlands.
Suzanna M
SM
van Walraven
Oxford University Hospitals NHS Trust, British Bone Marrow Donor Registry and Cord Blood Banks, NHS-BT, Oxford, United Kingdom.
Vanderson
V
Rocha
Foundation DKMS Polska, Warsaw, Poland.
Tigran
T
Torosian
FCM Santa Casa de São Paulo, Disciplina de Hematologia e Oncologia, São Paulo, Brasil.
Carmen
C
Vergueiro
Bone Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota.
Daniel
D
Weisdorf
Department of Cell Transplantation and Regenerative Medicine, Tokai University School of Medicine, Tokyo, Japan.
Hiromasa
H
Yabe
Department of Hematology, University Hospital Basel, Basel, Switzerland.
Jörg P
JP
Halter
D026683:Advisory Committees; D000367:Age Factors; D016026:Bone Marrow Transplantation / Q000379:methods*; D000066491:Clinical Decision-Making / Q000941:ethics*; D032921:Consensus; D006304:Health Status; D019337:Hematologic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006650:Histocompatibility Testing; D006801:Humans; D007258:Informed Consent; D007391:International Cooperation; D012306:Risk; D035781:Siblings; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D061349:Unrelated Donors
Related stem cell donor; Suitability criteria